Business Wire

Toshiba to Showcase the Next Generation of Retail Innovations at First NRF Retail’s Big Show in Europe

1.9.2025 18:00:00 CEST | Business Wire | Press Release

Share

Toshiba Global Commerce Solutions will showcase how the latest retail innovations are empowering retailers to craft unique journeys and sustainably deliver success in booth #G167 - Pavilion 6 at the first-ever NRF 2025: Retail’s Big Show Europe this month. Toshiba’s new modular and customized solutions utilize advanced technology like AI, computer vision, and machine learning to meet the unique needs of retailers, no matter their size or segment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250901613943/en/

Toshiba Global Commerce Solutions will showcase how the latest retail innovations are empowering retailers to craft unique journeys and sustainably deliver success in booth #G167 - Pavilion 6 at the first-ever NRF 2025: Retail’s Big Show Europe this month.

NRF attendees will experience Toshiba’s broad portfolio of:

  • Next generation Point-of-Sale (POS) solutions, including the new TCx® 620, TCx® 820, and TCx️® Touch Displays, are Toshiba’s most adaptable and versatile POS systems to date. From sleek and durable TCx® 820, to the compact and powerful TCx® 620, these solutions create tailored checkout experiences that adapt and grow with changing business needs.
  • Modular self-checkout solutions powered by AI and computer vision that can tailor the shopping experience in any retail environment. With ELERA® Loss Prevention and ELERA® Produce Recognition, retailers gain real-time insights to prevent loss, increase checkout speed, and evolve with future-ready technology.
  • Innovativesoftware ranging from integrated suites to microservice-based platforms powered by AI to support retail media with personalized shopping experiences. Retailers benefit from additional AI capabilities to accurately measure ROAS, shopper engagement, and in-store conversations.

“NRF brings together retail leaders and innovators to shape the future of commerce, and it’s especially exciting to see NRF expand to Europe for the first time. As an established global leader, we’re thrilled to showcase how our latest innovations help retailers create smarter, more secure, and more sustainable shopping experiences,” said Andrew McDaniel, Managing Director and Senior VP Europe at Toshiba Global Commerce Solutions. “Toshiba is proud to be part of this milestone moment, and we’re looking forward to connecting with retailers in Paris to share how we can support their technology journey from the back office to the front of the store.”

Toshiba’s booth will also feature the latest integrated AI innovations with Toshiba’s partner Catch. Event attendees will experience how Catch AI seamlessly integrates with Toshiba’s ELERA® Commerce Platform to reshape physical retail through real-time personalization, behavioral insights, and in-store retail media. With these integrated solutions, retailers can monetize in-store traffic with high-performing retail media, optimize operations using real-time behavioral data, and elevate the customer experience.

NRF Retail’s Big Show Europe will be from September 16 – 18 at the Paris Expo Porte de Versailles. Click here to schedule a meeting with Toshiba and learn more about the solutions and retail industry trends.

Latest Industry Insights and Media Coverage
-Redefining retail security: how to empower people while protecting profits
-Matalan Partners with Toshiba Global Commerce Solutions to Enhance In-Store Experience
-Creating a Positive Customer Experience in Self-Checkout (Video)

About Toshiba Global Commerce Solutions:
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs.
Visit commerce.toshiba.com and engage with us on:
LinkedIn / YouTube / Facebook / Instagram: @toshibacommerce /
X/Twitter: @ToshibaCommerce

Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250901613943/en/

Contacts

MEDIA CONTACT:
Toshiba Global Commerce Solutions
Anne-Francoise Ribot
Anne.Ribot@toshibagcs.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye